NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

"Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare

James W. Hughes, Michael J. Moore, Edward A. Snyder

NBER Working Paper No. 9229
Issued in September 2002
NBER Program(s):   HC   HE

We analyze the effects on consumers of an extreme policy experiment -- Napsterizing' pharmaceuticals -- whereby all patent rights on branded prescription drugs are eliminated for both existing and future prescription drugs without compensation to the patent holders. The question of whether this policy maximizes consumer welfare cannot be resolved on an a priori basis due to an obvious tradeoff: While accelerating generic entry will yield substantial gains in consumer surplus associated with greater access to the current stock of pharmaceuticals, future consumers will be harmed by reducing the flow of new pharmaceuticals to the market. Our estimates of the consumer surpluses at stake are based on the stylized facts concerning how generic entry has affected prices, outputs, and market shares. We find that providing greater access to the current stock of prescription drugs yields large benefits to existing consumers. However, realizing those benefits has a substantially greater cost in terms of lost consumer benefits from reductions in the flow of new drugs. Specifically, the model yields the result that for every dollar in consumer benefit realized from providing greater access to the current stock, future consumers would be harmed at a rate of three dollars in present value terms from reduced future innovation. We obtain this result even accounting for the stylized fact that after generic entry branded drugs continue to earn significant price premia over generic products and hence recognizing that Napsterizing does not completely eliminate the incentives to innovate.

download in pdf format
   (1240 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (1240 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w9229

Users who downloaded this paper also downloaded these:
Berndt, Kyle, and Ling The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches
Lichtenberg w8996 Benefits and Costs of Newer Drugs: An Update
Danzon, Epstein, and Nicholson w10536 Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
Chaudhuri, Goldberg, and Barwick w10159 Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India
Lichtenberg and Waldfogel w9750 Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us